Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C
| Autor: | S. Boccia, E. Minola, L. Lomonaco, P. Fabris, C. Paternoster, E. Castagnetti, Irene Zagni, Chiara Scattolini, Alessandro Tagger, M Giusti, A. Tonon, G. Abbati, G. Tositti, M. Pantalena, A. Redaelli, M. Distasi, P. Rovere, S. Suppressa, G. Fornaciari, Giovanna Fattovich, R. Montanari, M. Felder, C. Rizzo |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Combination therapy Hepatitis C virus Hepacivirus Interferon alpha-2 medicine.disease_cause Antiviral Agents Group A Gastroenterology Group B chemistry.chemical_compound Recurrence Interferon Virology Internal medicine Ribavirin Clinical endpoint Humans Medicine Hepatology Reverse Transcriptase Polymerase Chain Reaction business.industry Interferon-alpha Hepatitis C Chronic Recombinant Proteins Regimen Logistic Models Treatment Outcome Infectious Diseases chemistry Immunology RNA Viral Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Journal of Viral Hepatitis. 10:111-117 |
| ISSN: | 1365-2893 1352-0504 |
| DOI: | 10.1046/j.1365-2893.2003.00409.x |
| Popis: | summary. Retreatment of relapser patients with chronic hepatitis C with the standard dose of interferon (IFN) of 3 million units (MU) thrice weekly (tiw) plus ribavirin for 24 weeks achieves a sustained response in 30 and 73% of patients with genotype 1 and 2 or 3, respectively. The aim of this study was to evaluate the efficacy and safety of IFN alpha-2b induction therapy, followed by prolonged treatment with a high dose of IFN alpha-2b plus ribavirin in relapser patients. A total of 119 patients were randomized to receive IFN alpha-2b 5 MU daily (Group A: 59 patients) or IFN alpha-2b 5 MU tiw (Group B: 60 patients) for 4 weeks followed by IFN (5 MU tiw) and ribavirin (1000-1200 mg/day) for 48 weeks in both groups. The primary end point was hepatitis C virus (HCV)-RNA clearance at week 24 after the end of treatment. A sustained virological response (SVR) was achieved in 68 and 60% of Group A and B patients, respectively (P = 0.37). Logistic regression analysis identified genotype 2 or 3 as the only independent factor associated with response, whereas induction regimen and baseline viraemia levels did not affect the response. The overall SVR was 53 and 72% in patients with genotype 1 or 4 and 2 or 3, respectively. In conclusion, induction IFN therapy does not enhance the SVR to a 48-week combination therapy. Our study suggests that relapsed patients with genotype 1 or 4 may achieve significant response rates of approximately 50%, if retreated with 5 MU tiw IFN plus ribavirin for 48 weeks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|